Therapy Detail

Therapy Name Varlitinib
Synonym
Therapy Description

Varlitinib is a selective inhibitor of EGFR and ERBB2 (HER2), which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation and increased cell death (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Varlitinib ARRY-334543|ARRY-543 EGFR Inhibitor (Pan) 42 HER2 Inhibitor 21 Varlitinib is a selective inhibitor of EGFR and ERBB2 (HER2), which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation and increased cell death (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 positive Her2-receptor positive breast cancer sensitive Varlitinib Phase I Actionable In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603). detail...
ERBB2 over exp stomach cancer sensitive Varlitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74% tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150). detail...
Unknown unknown Advanced Solid Tumor not applicable Varlitinib Phase I Actionable In a Phase I clinical trial, Varlitinib (ARRY-334543) demonstrated safety and some preliminary anti-tumor activity in patients with advanced solid tumors (Mol Cancer Ther 2009;8(12 Suppl):B54). detail...
Clinical Trial Phase Therapies Title Recruitment Status